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Abstract
Antiplatelet drugs plays important role in the therapy of atherothrombosis. Dual antiplatelet therapy 
is recommended as a strategy for the prevention of stent thrombosis in patients who underwent 
Percutaneus Coronary Intervention (PCI). In combination with aspirin, tienoperidine is currently 
the drug of choice to prevent stent thrombosis. The issue of the high inter-individual variability of 
response is clinically relevant, since poor responders are not adequately protected from major 
adverse cardiac events (MACE). We reported a 62-years old woman underwent primary PCI with 
implantation of BAS. She was later known to have in-stent thrombosis in the LAD after repeated 
angiography. The probable cause for the later cardiac event in this patient were overlapped stent, 
small vessel diameter, diabetes mellitus, and the patients also shown a persistent platelet reactivity 
despite clopidogrel therapy. We administered this patient with pasugrel as antiplatelet replacing 
clopidogrel and the patient was managed without ischemic symptoms afterwards.
Introduction
Antiplatelet drugs plays important role in 
the therapy of atherothrombosis. Dual antiplatelet 
therapy is recommended as a strategy for the 
prevention of stent thrombosis in patients who 
underwent Percutaneus Coronary Intervention 
(PCI). In combination with aspirin, tienoperidin 
is currently the drug of choice to prevent stent 
thrombosis. Stent thrombosis remains an important 
and potentially lethal clinical problem (incidence-
0.9%, mortality-8.9%). To date, clopidogrel, a 
second generation of tienoperidin has replaced 
ticlopidin due to its tolerability evidenced in 
CLASSIC trial – Clopidogrel Aspirin International 
Cooperative (Bertrand et al., 2000; Campo et al., 
2010). 
Clopidrogel P2Y12 has a very selective 
tissue distribution, making it an attractive molecular 
target for therapeutic intervention. Indeed, 
P2Y12 is the target of effi cacious antithrombotic 
agents. It is a pro-drug that need to be converted 
in vivo to active metabolites by the hepatic 
cytochrome P-450 (CYP). Their active metabolite 
then binds to P2Y12, forming a disulfi de bond 
with a cysteine residue of the receptor, thereby 
irreversibly inhibiting it (Cattaneo and Podda, 
2010). Despite its proven antithrombotic effi cacy, 
clopidogrel lacks some important features of the 
ideal antithrombotic agent The issue of the high 
inter-individual variability of response is clinically 
relevant, since poor responders are not adequately 
protected from major adverse cardiac events 
(MACE). Several studies show that about one-
third of treated patients do not display adequate 
inhibition of P2Y12-dependent platelet function 
(‘‘clopidogrel resistance’’). This is associated with 
loss of function mutations of CYP isoform, and with 
interference with common adjunctive medications, 
such as proton pump inhibitors (PPI) and other 
conditions (Cattaneo and Podda, 2010) . 
Despite the unambiguous clinical benefi t 
achieved with the adjunct of clopidogrel in ACS/
PCI patients, a considerable number of patients 
continue to have cardiovascular events. This 
has been, in part, attributed to the fact than 
some patients may have poor clopidogrel-
induced antiplatelet effects. These patients, 
in fact, despite treatment with clopidogrel, 
persist with enhanced platelet reactivity, which is 
pivotal for the development of atherothrombotic 
complications (Angiolillo et al., 2007; Wiviott, 
2006). Several mechanism were proposed for 
the individual variability response to clopidogrel 
including metabolic activity CYP450 which are 
interaction to other drugs or the presence of 
genetic polymorphism in coding gen CYP450, as 
well as the cellular factor, i.e, platelet reactivity, 
clinical condition, drug compliance and underlying 
risk factors (Gurbel and Tantry, 2011). 
This case review will discuss on the 
clopidogrel resistance in patients who suffered 
from coronary stent thrombosis after bio-active 
stent (BAS) implantation as well the strategy for 
antiplatelet administration after intervention. 
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Case
We reported a 62-years old female who 
came to the emergency department of RSUP dr. 
Sardjito. She was having infarction type chest 
pain 4.5 hours prior to the admission. The risk 
factors of this patient were hypertension, poorly 
controlled diabetes mellitus, dyslipidemia and 
obesity. On arrival, the physical examination 
revealed that her blood pressure was 110/70 
mmHg, pulse 70x/minutes, respiration rate 
was respirasi 20x/minutes. We did not find 
Figure 1. ECG tracing of the patient in the emergency unit with infarction type 
angina. The picture showed an ST segmen elevation in anterior 
extensive area (I, aVL, V1-V6 ).
Figure 2. First coronary angiography at the time of STEMI before Primary PCI. (A). Totally occluded 
vessel at mid LAD as culprit lesion (B). Reperfused LAD after BAS implantation 
A B  
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any signs and symptoms for heart failure. The 
electrocardiography examination showed sinus 
rhythm, with the heart rate 70x/minutes, and there 
was an ST segmen elevation on the I, aVL, V1-V6 
leads with the reciprocal ST segmen depression 
in di II, aVF (fi gure 1). There was no abnormlity 
in the head and neck examination. The cardiac 
physical examination revealed an enlargement of 
the heart, without changing in the 1st and 2nd heart 
sound. We could not fi nd any gallop nor murmur. 
Lung examination was clear and the abdominal 
condition was normal. 
Laboratory examinations showed creatinine 
kinase (CK) 91U/L; creatinin kinase MB (CKMB) 23 
U/L; Troponin-I 0.06 ug/L; total cholesterol 199 mg/
dl; high density lipoprotein (HDL) 37.3 mg/dl; low 
density lipoprotein (LDL) 146 mg/dl; trygliseride 44 
mg/dl; dan random blood glucose 440 mg/dl.
Based on the data above we diagnosed this 
patient as having anterior extensive ST-elevation 
myocardial infarction/STEMI onset 4.5 jam 
Killip I. The patient received aspirin 320 mg and 
clopidrogel 300 mg and proceed for primary PCI. 
Coronary angiography revealed a total occlusion 
in the mid Left Anterior Descenden (LAD) that was 
thought as a culprit lesion, a normal Left Main 
(LM), a normal Left Circumfl ex (LCx) and Right 
Coronary Artery (RCA). 
We further performed coronary intervention 
in this patient with balloon predilatation size 2.0/15 
mm 10-16 atm and the bio-active stent (TITAN®) 
implantation n sized 2.75/19 mm overlapped 
with size 2.5/16 mm in the culprit lesion, with 
nitrogliserin infusion 2.5 ug/minutes as well as 
6000 unit heparin intraveously. At the end we 
showed improvement in the coronary fl ow with 
TIMI score 3 without any residual lesion (Figure 
2). Eptifibatide infusion 2 ug/kg/minutes were 
administered after the stent implantation. 
Patient was then hospitalized in ICCU for 5 
days with medical treatments consisting aspirin 
160mg/day, clopidogrel 75 mg/12 hour, captopril 
6.25 mg/8 hour, isosorbid dinitrate (ISDN) 5 mg/8 
hour, atorvastatin 40 mg/24 hour, basal insulin 20 
unit-0-0 dan mixture 8-8-8, bisoprolol 1.25 mg/24 
hour. During hospitalization, there was an event of 
stable ventricular tachycardia that was maintained 
using amiodaron bolus 150 mg followed by 1 
mg/minute, 0.5 mg/minute, and orally 200 mg/8 
hour. 
One month later, patient was complaining 
of reccurent angina on effort, but there was no 
Figure 3. ECG record revealed an old myocardial infarction (I, avL, dan V1-
V5). 
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ECG change on the outpatient examination. The 
diagnosis was Stable Angina Pectoris CCS II. 
We continued the dual antiplatelet therapy using 
aspirin 80mg dan clopidogrel 75 mg daily. Three 
months after the infarction, the patient was having 
another episode of recurrent angina which was 
frequent and increased in intensity and clinically 
diagnosed as unstable angina pectoris. The vital 
sign was stable with BP 110/70 mmHg, pulse 
70x/minute, and respiratory rate 18x/minute.  The 
ECG examination showed sinus rhythm with old 
miocardial infarction (Figure 3). There was no 
increase in cardiac marker with the levels of CK 
46U/L, CKMB 15U/L, and Troponin-I <0.01. The 
lady was then admitted in ICCU as suspected stent 
thrombosis. During hospitalization, she frequently 
complained of having resting angina without any 
changes in ECG tracing, thus another coronary 
angiography was then performed. 
On coronary angiography evaluation, we 
found a totally occluded in mid LAD which was 
previously implanted by BAS. In addition, there 
was an 80% stenosis in LCx (Figure 4). Another 
intervention was then performed in LAD using 
A B 
Figure 4. Second coronary angiography as compared to the fi rst one at the time of primary 
PCI A. In stent occlusion on second angiography B. totally occluded LAD at fi rst 
angiography at the time of primary PCI 
Figure 5. Angiography after second intervention with another balloon 
dilatation on the in stent trombosis vessel, showing residual 
stenosis 
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staged balloning with coronary balloon sized 1.5/20 
mm and 2.5/20 mm and using 14 atm pressures. Due 
to some diffi culties in the procedure, nitroglycerin 
200 ug and eptifi batide was administered before 
balloon infl ation. For the LCx lesion, we performed 
balloon dilatation using 2.5/20 mm on 10 atm and 
the implantation of bare metal stent (BMS) sized 
2.75/20 mm. The fi nal result was 30% residual 
stenosis in LAD (fi gure 5).  
The patients was considered of having an 
antiplatelet resistance that may cause the in stent 
thrombosis. Therefore we performed a platelet 
aggregation test for aspirin and clopidogrel using 
light transmission agregometer method (Verify-
Now, San Diego, California) untuk melihat efek 
aspirin dan clopidogrel. The results showed a good 
inhibition of platelet aggregation by aspirin (ARU 
419; normal <550) and a minimal response by 
clopidogrel (Inhibitory effect by 13% from normal 
range 40-60%). The plateler reactivity showed 
remaining high level with PRU 298 from base 341; 
normal <230. Based on the result, the patient was 
categorized as a non responder to clopidogrel or 
having clopidogrel resistance. 
The patient was then discharged from the 
hospital after we administered new antiplatelet to 
replace clopidogrel. The agent given to her was 
pasugrel 10 mg/hari. There was no complaint after 
the new medication.  
Discussion
Thrombosis and restenosis in coronary stent 
could manifest as a recurrent angina. According to the 
American Research Concorcium, stent thrombosis 
was classifi ed based on time which are early stent 
thrombosis ( 0-1 month), late stent thrombosis (1 
month – 1 year), and very late stent thrombosis 
(>1 year). The defi nite diagnosis is based on the 
coronary angiography that revealed a thrombus 
in the previous stent or 5 mm proximal or distal to 
the previous stent. (Lemesle et al., 2008). In stent 
restenosis (ISR) is a restenosis in the previous stent 
with the degree of stenosis >50%. ISR was classifi ed 
as focal when the lesion <10mm or diffuse when the 
lesion >10 mm (Mitra and Agrawal, 2006). On the 
case above, the recurrent and progressif angina 2 
month post BAS implantation and supported by the 
evaluation of coronary angiography revealing a total 
occlusion in the previous stent showed a late stent 
trombosis with differential diagnosis as an in-stent 
restenosis. 
Several predictor for stent thrombosis 
are stent implantation in the small diameter 
vessel, multiple lesion, stent implantation in 
the long stenotic lesion, overlapped stenting, a 
bifurcation lesion, an apposition or suboptimal 
stent implantation, low EF, DM, renal impairement, 
acute coronary syndrome, and interruption in the 
antiplatelet administration including premature 
cessation and the drug compliance (Wijns et al., 
2010). The predictor in this patient were small 
vessel, overlapped stent, DM, and STEMI. 
To prevent ST or ISR, a normal response to 
platelet aggregation should be inhibited. Several 
drugs has been approved for this purpose, i.e. 
aspirin, tienoperidine, as well as glycoprotein IIb/
IIIa inhibitor (Gurbel et al., 2003). Several clinical 
trials showed that clopidogrel was better tolerated 
than ticlopidine and was associated with lower 
side effect. The optimal dose for clopidogrel to 
inhibit platelet aggregation post PCI procedure is 
300 – 600 mg as a loading dose continued by 75 
mg daily (Vats et al., 2006). The use of clopidogrel 
as recommended dual antiplatelet with aspirin 
has been showed in the CREDO trials, to reduce 
cardiovascular event post PCI as 38.6% consisting 
of death, myocardial infarction, and repeat 
revascularization after 4 weeks of treatment. 
(Eriksson, 2004). Guidelines showed that for 
patients with STEMI, NSTEMI, and for those who 
underwent PCI recommends the dual antiplatelet 
yaitu aspirin 80 – 325 mg and clopidogrel 75 – 300 
mg or pasugrel 10 mg (Wijns et al., 2010). 
When a stent thrombosis occur after the 
administration of the dual antiplatelet therapy, 
we need to consider several factors that may 
interrupt with the inadequacy of that DAPT i.e, : 
(1) compliance; (2) hypercoagulability state; (3) 
drug resistance.  A study involving 60 STEMI 
patients who underwent primary PCI showed 
that those who did not respon to clopidogrel had 
increase risk of cardiac event vary from NSTEMI 
to recurrent STEMI (Matetzky et al., 2004). In 
our patient, the compliance to DAPT was good, 
however there was risk of having hypercoagulable 
state and increase in the platelet reactivity due to 
diabetes. Thus, the antiplatelet resistance in our 
patient should be considered as one factor for the 
in-stent occlusion. 
Several studies showed that the degree 
for platelet inhibition vary individually. Patient 
who is resistant often called as a non responder 
or hyporensponder. According to the platelet 
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aggregation status, the clopidogrel resistance is 
the failure of clopidogrel to inhibit the targeted 
platelet thus showing a high degree of platelet 
reactivity. The absolute inhibitory is ~ 10% (Gurbel 
and Tantry, 2007). When a resistance is suspected, 
the platelet function test is recommended. Several 
methods has been established, e.g. platelet 
agregometry, fl ow cytometry or phosphorilation 
test with vasodilatory stimulus (Vats et al., 2006). 
To date, the platelet function test with most 
reliable data is light transmittance aggregometry 
(LTA), modifi ed thromboelastography, and platelet 
function analyzer-100 (-100®, Dade international, 
inc., Deerfi eld, IL) as well as point-of-care assay 
using accumetrics (Verify-Now®, San Diego, 
California) (Gorog et al., 2009). An accumetric 
test  only needs 10 – 15 minutes and is reported 
as P2Y12 reaction unit (PRU), inhibitory level and 
the baseline value. In our case, we performed 
a platelet aggregation test using Verify-Now® 
showing low platelet inhibitory level as much as 
13% and high platelet reactivity. 
There are some factors contributes to the 
low platelet response to clopidogrel, i.e, cellular 
factor which are increase in the activity of P2Y12, 
the increase in platelet turnover, the increase 
in ADP exposure, drug interaction and genetic 
factor. Genetic factor occur when there is genetic 
polymorphism of hepatic enzymes-encoded gene 
such as CYP2P3A and CYP2P19 (Azam and 
Jozic, 2009). Figure 6 showed the clopidogrel 
mechanism.
The management for those who is resistant 
to clopidogrel is either to increase the daily dose 
of clopidogrel or to replace with other type of 
tienoperidine. GRAVITAS study used P2Y12 test 
with VerifyNow in patient who underwent PCI with 
DES to differentiate responsive or nonresponsive 
group of clopidogrel and to evaluate the cardiac 
event in patient with high dose clopidogrel 
versus low dose one (Azam and Jozic, 2009). 
Another study VASP-02 (vasodilator-stimulated 
phospoprotein 2) showed reduced platelet 
reactivity with maintenance dose of 150 mg daily 
(Aleil et al., 2008). 
Pasugre l  and  t i cag re lo r  cu r ren t l y 
recommended as the tienoperidine for antiplatelet 
agent as combine to aspirin in patients post 
infacrtion or after stent implantation. Pasugrel is 
a 3rd generation of tienoperidine and metabolizes 
more effi ciently than clopidogrel. Ticagrelor has 
recently been added to the latest guidelines for 
the management of ACS patients and post stent 
implantation antiplatelet agent. It passes the liver 
metabolism and have shorter duration of action 
(Wiviott et al., 2007). 
 
Figure 6. Clopidogrel mechanism and the role of genetic factors
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Conclusion
We reported a 62 years-old female with 
recurrent angina and cardiovascular event after stent 
implantation based on STEMI indication. We found 
that there was in stent re-occlusion in the previous 
BAS which was considered as in-stent thrombosis or 
restenosis. The risk factor for the in stent occlusion 
in this patient was overlapped stent, small vessel 
diameter, DM, left ventricular dysfunction and 
the clopidogrel resistance. The patient was then 
well managed with the combination of aspirin and 
pasugrel as the dual antiplatelet agent. 
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